Literature DB >> 6427703

Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.

L O Frøholm, B P Berdal, K Bøvre, P Gaustad, A Harboe, E Holten, E A Høiby, A Lystad, T Omland, C E Frasch.   

Abstract

A combined serogroup B capsular polysaccharide and serotype 2a outer membrane complex meningococcal vaccine and a placebo preparation were tested double-blindly in 55 adult, male volunteers. The vaccine gave twofold increased binding antibodies, measured by ELISA, against non-capsular outer membrane antigen in 85 per cent of those vaccinated. Bactericidal antibodies towards a meningococcal serogroup C serotype 2a strain also increased fourfold or more among 85% vaccinated. New acquisition of meningococcal carriage was associated with antibody increase in one person from the placebo group.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6427703

Source DB:  PubMed          Journal:  NIPH Ann        ISSN: 0332-5652


  7 in total

1.  Meningococcal disease in Canada: surveillance summary to 1987.

Authors:  P V Varughese
Journal:  CMAJ       Date:  1989-09-15       Impact factor: 8.262

2.  Human opsonins to meningococci after vaccination.

Authors:  A Halstensen; B Haneberg; L O Frøholm; V Lehmann; C E Frasch; C O Solberg
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

3.  Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine.

Authors:  E Wedege; T E Michaelsen
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

4.  Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting.

Authors:  E Wedege; L O Frøholm
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

5.  Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors:  L Y Wang; C E Frasch
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

6.  Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.

Authors:  E Rosenqvist; S Harthug; L O Frøholm; E A Høiby; K Bøvre; W D Zollinger
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

7.  Immune responses in mice to different noncovalent complexes of meningococcal B polysaccharide and outer membrane proteins.

Authors:  M R Lifely; Z Wang
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.